Efficient remediation of soils contaminated with petroleum hydrocarbons using sustainable plant-derived surfactants.

Surfactant-enhanced multiphase extraction is recognized as an effective method to remove petroleum related contaminants from soil. Owing to the high biodegradability and low biotoxicity, plant-derived surfactants are considered as promising alternatives to synthetic surfactants. In this study, two plant surfactants were respectively extracted from Sapindus mukorossi (PS-1) and Fructus Gleditsiae sinensis (PS-2). Component analysis and chemical structure characterization indicated that triterpenoid saponins were the main components of both plant surfactants. The removal efficiency of tetradecane by PS-1 and PS-2 was 75.6% and 62.2%, respectively, which was comparable with that by Tween-80. The results were validated by column leaching experiments. The abundant hydroxyl, aldehyde and epoxy groups in the plant surfactants made them readily self-assemble to form micelles via hydrogen bonding and van der Waals interactions, which promoted the solubilization of tetradecane in the liquid phase, particularly at appropriate ionic strength and temperature. Due to the reduced electrostatic attraction by the acidic and ionizable functional groups in the plant surfactants, their sorption capacities (0.15 and 0.24 g1-n Ln·kg-1 for PS-1 and PS-2, respectively) onto the soil were much lower than that of Tween-80, making them much easier to be extracted from contaminated soil. This study would deepen our understanding to improve the performances of plant surfactants in petroleum hydrocarbons-contaminated soil remediation.

Parasite-Derived Excretory-Secretory Products Alleviate Gut Microbiota Dysbiosis and Improve Cognitive Impairment Induced by a High-Fat Diet.

High-fat (HF) diet-induced neuroinflammation and cognitive decline in humans and animals have been associated with microbiota dysbiosis via the gut-brain axis. Our previous studies revealed that excretory-secretory products (ESPs) derived from the larval Echinococcus granulosus (E. granulosus) function as immunomodulators to reduce the inflammatory response, while the parasitic infection alleviates metabolic disorders in the host. However, whether ESPs can improve cognitive impairment under obese conditions remain unknown. This study aimed to investigate the effects of E. granulosus-derived ESPs on cognitive function and the microbiota-gut-brain axis in obese mice. We demonstrated that ESPs supplementation prevented HF diet-induced cognitive impairment, which was assessed behaviorally by nest building, object location, novel object recognition, temporal order memory, and Y-maze memory tests. In the hippocampus (HIP) and prefrontal cortex (PFC), ESPs suppressed neuroinflammation and HF diet-induced activation of the microglia and astrocytes. Moreover, ESPs supplementation improved the synaptic ultrastructural impairments and increased both pre- and postsynaptic protein levels in the HIP and PFC compared to the HF diet-treated group. In the colon, ESPs reversed the HF diet-induced gut barrier dysfunction, increased the thickness of colonic mucus, upregulated the expression of zonula occludens-1 (ZO-1), attenuated the translocation of bacterial endotoxins, and decreased the colon inflammation. Notably, ESPs supplementation alleviated the HF diet-induced microbiota dysbiosis. After clarifying the role of antibiotics in obese mice, we found that broad-spectrum antibiotic intervention abrogated the effects of ESPs on improving the gut microbiota dysbiosis and cognitive decline. Overall, the present study revealed for the first time that the parasite-derived ESPs alleviate gut microbiota dysbiosis and improve cognitive impairment induced by a high-fat diet. This finding suggests that parasite-derived molecules may be used to explore novel drug candidates against obesity-associated neurodegenerative diseases.

Adjuvant therapy for hepatocellular carcinoma: current situation and prospect.

Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide, accounting for 90% of primary liver cancers, and its incidence is still increasing. While the curative treatment for HCC is surgical resection and liver transplantation, most patients are in advanced stage, and lose the chance of surgery. Other palliative treatments include radiofrequency ablation, transarterial embolization, chemotherapy, and radiotherapy. Although there are so many treatments, the prognosis of HCC is still very poor. A major obstacle for the treatment for HCC is the high frequency of tumor recurrence even after curative resection and liver transplantation. Since HCC is frequently resistant to conventional chemotherapy and radiotherapy, clinical development of novel therapeutic agents against HCC has begun in earnest. Thus far, a series of adjuvant therapies for HCC have emerged, including small molecular target agents, monocolonal antibodies, microRNA, and Chinese herbal medicine. Some agents such as sorafenib have shown an advantage in prolonging the overall survival time, and has been approved by FDA for the treatment of advanced HCC. In this article we review the current situation and prospects of adjuvant therapies for HCC.